{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:19:33Z","timestamp":1791994773928,"version":"4.4.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-21719-7","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T15:38:42Z","timestamp":1761752322000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Targeting of SKP2 to combat drug resistance in multiple myeloma"],"prefix":"10.1038","volume":"15","author":[{"given":"Omar","family":"Faruq","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Ngo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonahunnatha","family":"Nesson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariusz","family":"Shrestha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"key":"21719_CR1","doi-asserted-by":"publisher","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","volume":"111","author":"RA Kyle","year":"2008","unstructured":"Kyle, R. A. & Rajkumar, S. V. Multiple myeloma. Blood 111, 2962\u20132972 (2008).","journal-title":"Blood"},{"key":"21719_CR2","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/ajh.25791","volume":"95","author":"SV Rajkumar","year":"2020","unstructured":"Rajkumar, S. V. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am. J. Hematol. 95, 548\u2013567 (2020).","journal-title":"Am. J. Hematol."},{"key":"21719_CR3","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s40262-018-0679-9","volume":"58","author":"CRC Tan","year":"2019","unstructured":"Tan, C. R. C., Abdul-Majeed, S., Cael, B. & Barta, S. K. Clinical pharmacokinetics and pharmacodynamics of bortezomib. Clin. Pharmacokinet. 58, 157\u2013168 (2019).","journal-title":"Clin. Pharmacokinet."},{"key":"21719_CR4","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1182\/blood-2008-04-149385","volume":"112","author":"AA Argyriou","year":"2008","unstructured":"Argyriou, A. A., Iconomou, G. & Kalofonos, H. P. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 112, 1593\u20131599 (2008).","journal-title":"Blood"},{"key":"21719_CR5","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.18632\/oncotarget.1497","volume":"4","author":"J Abdi","year":"2013","unstructured":"Abdi, J., Chen, G. & Chang, H. Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms. Oncotarget 4, 2186\u20132207 (2013).","journal-title":"Oncotarget"},{"key":"21719_CR6","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ctrv.2018.09.001","volume":"70","author":"P Robak","year":"2018","unstructured":"Robak, P., Drozdz, I., Szemraj, J. & Robak, T. Drug resistance in multiple myeloma. Cancer Treat. Rev. 70, 199\u2013208 (2018).","journal-title":"Cancer Treat. Rev."},{"key":"21719_CR7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s43556-021-00043-2","volume":"2","author":"Q Yang","year":"2021","unstructured":"Yang, Q., Zhao, J., Chen, D. & Wang, Y. E3 ubiquitin ligases: styles, structures and functions. Mol. Biomed. 2, 23 (2021).","journal-title":"Mol. Biomed."},{"key":"21719_CR8","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/s41580-021-00448-5","volume":"23","author":"DA Cruz Walma","year":"2022","unstructured":"Cruz Walma, D. A., Chen, Z., Bullock, A. N. & Yamada, K. M. Ubiquitin ligases: guardians of mammalian development. Nat. Rev. Mol. Cell. Biol. 23, 350\u2013367 (2022).","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"21719_CR9","doi-asserted-by":"publisher","first-page":"e1204","DOI":"10.1002\/ctm2.1204","volume":"13","author":"C Sampson","year":"2023","unstructured":"Sampson, C. et al. The roles of E3 ubiquitin ligases in cancer progression and targeted therapy. Clin. Transl. Med. 13, e1204 (2023).","journal-title":"Clin. Transl. Med."},{"key":"21719_CR10","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1002\/med.21675","volume":"40","author":"MD Asmamaw","year":"2020","unstructured":"Asmamaw, M. D., Liu, Y., Zheng, Y., Shi, X. & Liu, H. Skp2 in the ubiquitin-proteasome system: A comprehensive review. Med. Res. Rev. 40, 1920\u20131949 (2020).","journal-title":"Med. Res. Rev."},{"key":"21719_CR11","doi-asserted-by":"publisher","first-page":"5043","DOI":"10.1073\/pnas.081474898","volume":"98","author":"M Gstaiger","year":"2001","unstructured":"Gstaiger, M. et al. Skp2 is oncogenic and overexpressed in human cancers. Proc. Natl. Acad. Sci. 98, 5043\u20135048 (2001).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"21719_CR12","doi-asserted-by":"crossref","unstructured":"Yu, Z. K., Gervais, J. L. M. & Zhang, H. Human CUL-1 associates with the SKP1\/SKP2 complex and regulates p21 CIP1\/WAF1 and cyclin D proteins. Proc. Natl. Acad. Sci. 95, 11324\u201311329 (1998).","DOI":"10.1073\/pnas.95.19.11324"},{"key":"21719_CR13","first-page":"820","volume":"9","author":"M Filipits","year":"2003","unstructured":"Filipits, M. et al. Low p27Kip1 expression is an independent adverse prognostic factor in patients with multiple Myeloma1. Clin. Cancer Res. 9, 820\u2013826 (2003).","journal-title":"Clin. Cancer Res."},{"key":"21719_CR14","doi-asserted-by":"crossref","unstructured":"Kamura, T. et al. Degradation of p57 Kip2 mediated by SCF Skp2 -dependent ubiquitylation. Proc. Natl. Acad. Sci. 100, 10231\u201310236 (2003).","DOI":"10.1073\/pnas.1831009100"},{"key":"21719_CR15","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/35060126","volume":"3","author":"D Ganoth","year":"2001","unstructured":"Ganoth, D. et al. The cell-cycle regulatory protein Cks1 is required for SCFSkp2-mediated ubiquitinylation of p27. Nat. Cell. Biol. 3, 321\u2013324 (2001).","journal-title":"Nat. Cell. Biol."},{"key":"21719_CR16","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/j.chembiol.2012.09.015","volume":"19","author":"L Wu","year":"2012","unstructured":"Wu, L. et al. Specific small molecule inhibitors of Skp2-Mediated p27 degradation. Chem. Biol. 19, 1515\u20131524 (2012).","journal-title":"Chem. Biol."},{"key":"21719_CR17","doi-asserted-by":"publisher","first-page":"4297","DOI":"10.2147\/OTT.S203888","volume":"12","author":"H Zhao","year":"2019","unstructured":"Zhao, H. et al. SKP2 targeted inhibition suppresses human uveal melanoma progression by blocking ubiquitylation of p27. OncoTargets Ther. 12, 4297\u20134308 (2019).","journal-title":"OncoTargets Ther."},{"key":"21719_CR18","doi-asserted-by":"publisher","first-page":"e8412","DOI":"10.1590\/1414-431x20198412","volume":"52","author":"Y Yang","year":"2019","unstructured":"Yang, Y., Yan, W., Liu, Z. & Wei, M. Skp2 inhibitor SKPin C1 decreased viability and proliferation of multiple myeloma cells and induced apoptosis. Braz. J. Med. Biol. Res. 52, e8412 (2019).","journal-title":"Braz. J. Med. Biol. Res."},{"key":"21719_CR19","doi-asserted-by":"publisher","first-page":"6057","DOI":"10.1158\/1078-0432.CCR-04-2685","volume":"11","author":"R Buzzeo","year":"2005","unstructured":"Buzzeo, R. et al. Characterization of a R115777-resistant human multiple myeloma cell line with cross-resistance to PS-341. Clin. Cancer Res. 11, 6057\u20136064 (2005).","journal-title":"Clin. Cancer Res."},{"key":"21719_CR20","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1182\/blood.V79.1.213.213","volume":"79","author":"P Moalli","year":"1992","unstructured":"Moalli, P., Pillay, S., Weiner, D., Leikin, R. & Rosen, S. A mechanism of resistance to glucocorticoids in multiple myeloma: transient expression of a truncated glucocorticoid receptor mRNA. Blood 79, 213\u2013222 (1992).","journal-title":"Blood"},{"key":"21719_CR21","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.3390\/cancers14061592","volume":"14","author":"O Faruq","year":"2022","unstructured":"Faruq, O. et al. Targeting an MDM2\/MYC axis to overcome drug resistance in multiple myeloma. Cancers 14, 1592 (2022).","journal-title":"Cancers"},{"key":"21719_CR22","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40364-021-00296-7","volume":"9","author":"J Wu","year":"2021","unstructured":"Wu, J. et al. SMAD1 as a biomarker and potential therapeutic target in drug-resistant multiple myeloma. Biomark. Res. 9, 48 (2021).","journal-title":"Biomark. Res."},{"key":"21719_CR23","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar, S. V. et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 15, e538\u2013e548 (2014).","journal-title":"Lancet Oncol."},{"key":"21719_CR24","doi-asserted-by":"publisher","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","volume":"113","author":"O Landgren","year":"2009","unstructured":"Landgren, O. et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 113, 5412\u20135417 (2009).","journal-title":"Blood"},{"key":"21719_CR25","doi-asserted-by":"publisher","first-page":"5418","DOI":"10.1182\/blood-2008-12-195008","volume":"113","author":"BM Weiss","year":"2009","unstructured":"Weiss, B. M., Abadie, J., Verma, P., Howard, R. S. & Kuehl, W. M. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood. 113, 5418\u20135422 (2009).","journal-title":"Blood"},{"key":"21719_CR26","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1056\/NEJMoa070389","volume":"356","author":"RA Kyle","year":"2007","unstructured":"Kyle, R. A. et al. Clinical course and prognosis of smoldering (Asymptomatic) multiple myeloma. N. Engl. J. Med. 356, 2582\u20132590 (2007).","journal-title":"N. Engl. J. Med."},{"key":"21719_CR27","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1038\/nrc3818","volume":"14","author":"H Yu","year":"2014","unstructured":"Yu, H., Lee, H., Herrmann, A., Buettner, R. & Jove, R. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat. Rev. Cancer. 14, 736\u2013746 (2014).","journal-title":"Nat. Rev. Cancer"},{"key":"21719_CR28","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.immuni.2010.05.003","volume":"32","author":"L Durant","year":"2010","unstructured":"Durant, L. et al. Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis. Immunity 32, 605\u2013615 (2010).","journal-title":"Immunity"},{"key":"21719_CR29","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/0092-8674(95)90311-9","volume":"82","author":"Z Wen","year":"1995","unstructured":"Wen, Z., Zhong, Z. & Darnell, J. E. Maximal activation of transcription by Statl and stat3 requires both tyrosine and Serine phosphorylation. Cell 82, 241\u2013250 (1995).","journal-title":"Cell"},{"key":"21719_CR30","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12943-020-01258-7","volume":"19","author":"S Zou","year":"2020","unstructured":"Zou, S. et al. Targeting STAT3 in cancer immunotherapy. Mol. Cancer. 19, 145 (2020).","journal-title":"Mol. Cancer"},{"key":"21719_CR31","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41571-021-00549-2","volume":"19","author":"R Dhanasekaran","year":"2022","unstructured":"Dhanasekaran, R. et al. The MYC oncogene\u2014the grand orchestrator of cancer growth and immune evasion. Nat. Rev. Clin. Oncol. 19, 23\u201336 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"21719_CR32","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1002\/ajh.25758","volume":"95","author":"S Goldman-Mazur","year":"2020","unstructured":"Goldman-Mazur, S. et al. A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma. Am. J. Hematol. 95, 503\u2013509 (2020).","journal-title":"Am. J. Hematol."},{"key":"21719_CR33","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1182\/blood-2016-03-706077","volume":"128","author":"YW Qiang","year":"2016","unstructured":"Qiang, Y. W. et al. MAF protein mediates innate resistance to proteasome Inhibition therapy in multiple myeloma. Blood 128, 2919\u20132930 (2016).","journal-title":"Blood"},{"key":"21719_CR34","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan, A. J. et al. Diagnosis and management of multiple myeloma: A review. JAMA 327, 464 (2022).","journal-title":"JAMA"},{"key":"21719_CR35","doi-asserted-by":"publisher","first-page":"4457","DOI":"10.1182\/blood.V91.12.4457.412k48_4457_4463","volume":"91","author":"M Chesi","year":"1998","unstructured":"Chesi, M. et al. Frequent dysregulation of the c-maf Proto-Oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood 91, 4457\u20134463 (1998).","journal-title":"Blood"},{"key":"21719_CR36","doi-asserted-by":"publisher","first-page":"e202201543","DOI":"10.26508\/lsa.202201543","volume":"6","author":"S Chow","year":"2023","unstructured":"Chow, S. et al. Myeloma Immunoglobulin rearrangement and translocation detection through targeted capture sequencing. Life Sci. Alliance. 6, e202201543 (2023).","journal-title":"Life Sci. Alliance"},{"key":"21719_CR37","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"TC Chou","year":"2010","unstructured":"Chou, T. C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70, 440\u2013446 (2010).","journal-title":"Cancer Res."},{"key":"21719_CR38","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/leu.2016.258","volume":"31","author":"E Malek","year":"2017","unstructured":"Malek, E. et al. Pharmacogenomics and chemical library screens reveal a novel SCFSKP2 inhibitor that overcomes bortezomib resistance in multiple myeloma. Leukemia 31, 645\u2013653 (2017).","journal-title":"Leukemia"},{"key":"21719_CR39","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41392-023-01468-7","volume":"8","author":"C Xue","year":"2023","unstructured":"Xue, C. et al. Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer. Signal. Transduct. Target. Ther. 8, 204 (2023).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"21719_CR40","doi-asserted-by":"publisher","first-page":"731","DOI":"10.3390\/cancers11050731","volume":"11","author":"PSY Chong","year":"2019","unstructured":"Chong, P. S. Y., Chng, W. J. & De Mel, S. STAT3: A promising therapeutic target in multiple myeloma. Cancers 11, 731 (2019).","journal-title":"Cancers"},{"key":"21719_CR41","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.bbrc.2012.01.004","volume":"418","author":"H Huang","year":"2012","unstructured":"Huang, H., Zhao, W. & Yang, D. Stat3 induces oncogenic Skp2 expression in human cervical carcinoma cells. Biochem. Biophys. Res. Commun. 418, 186\u2013190 (2012).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"21719_CR42","doi-asserted-by":"publisher","first-page":"6508","DOI":"10.1128\/MCB.17.11.6508","volume":"17","author":"J Chung","year":"1997","unstructured":"Chung, J., Uchida, E., Grammer, T. C. & Blenis, J. STAT3 Serine phosphorylation by ERK-dependent and -independent pathways negatively modulates its tyrosine phosphorylation. Mol. Cell. Biol. 17, 6508\u20136516 (1997).","journal-title":"Mol. Cell. Biol."},{"key":"21719_CR43","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S1535-6108(04)00019-4","volume":"5","author":"EM Hurt","year":"2004","unstructured":"Hurt, E. M. et al. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell. 5, 191\u2013199 (2004).","journal-title":"Cancer Cell."},{"key":"21719_CR44","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nrc746","volume":"2","author":"WM Kuehl","year":"2002","unstructured":"Kuehl, W. M. & Bergsagel, P. L. Multiple myeloma: evolving genetic events and host interactions. Nat. Rev. Cancer. 2, 175\u2013187 (2002).","journal-title":"Nat. Rev. Cancer"},{"key":"21719_CR45","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/S1097-2765(03)00173-4","volume":"11","author":"SY Kim","year":"2003","unstructured":"Kim, S. Y., Herbst, A., Tworkowski, K. A., Salghetti, S. E. & Tansey, W. P. Skp2 regulates Myc protein stability and activity. Mol. Cell. 11, 1177\u20131188 (2003).","journal-title":"Mol. Cell."},{"key":"21719_CR46","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/S1097-2765(03)00193-X","volume":"11","author":"D Von Lehr","year":"2003","unstructured":"Von Lehr, D. The F-Box protein Skp2 participates in c-Myc proteosomal degradation and acts as a cofactor for c-Myc-regulated transcription. Mol. Cell. 11, 1189\u20131200 (2003).","journal-title":"Mol. Cell."},{"key":"21719_CR47","doi-asserted-by":"crossref","unstructured":"Llombart, V. & Mansour, M. R. Therapeutic targeting of undruggable MYC. eBioMedicine. 75, 103756 (2022).","DOI":"10.1016\/j.ebiom.2021.103756"},{"key":"21719_CR48","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41408-024-01147-y","volume":"14","author":"J Yoon","year":"2024","unstructured":"Yoon, J., Jeon, T., Kwon, J. A. & Yoon, S. Y. Characterization of MYC rearrangements in multiple myeloma: an optical genome mapping approach. Blood Cancer J. 14, 165 (2024).","journal-title":"Blood Cancer J."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-21719-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-21719-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-21719-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T16:07:35Z","timestamp":1761754055000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-21719-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["21719"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-21719-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]},"assertion":[{"value":"12 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37838"}}